Hydroxyurea: a key player in cancer chemotherapy

References

• Cantwell BMJ, Veale D, Rivette C, Ghani S, Harris AL. Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair, a Phase II study in non-small-cell lung cancer. Cancer Chemother. Pharmacol.23, 252–254 (1989).
   PubMedGoogle Scholar
• Finch RA, Liu MC, Grill SP et al. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol.59, 983–991 (2000).
   PubMed Web of Science ®Google Scholar
• Smith DC, Vaughan WP, Gwilt PR, Trump DL. A Phase I trial of high-dose continuous-infusion hydroxyurea. Cancer Chemother. Pharmacol.33, 139–143 (1993).
   PubMedGoogle Scholar
• Ford SS, Shackney SC. Lethal and sublethal effects of hydroxyurea in relation to drug comcentration and duration of drug exposure in sarcoma 180 in vitro. Cancer Res.37, 2628–2637 (1977).
   PubMedGoogle Scholar
• Moran RE, Straus MJ. Cytokinetic analysis of L1210 leukemia after continuous infusion of hydroxyurea in vivo. Cancer Res.39, 1616–1622 (1979).
   PubMedGoogle Scholar
• Heeney MM, Whorton MR, Howard TA, Johnson CA, Ware RE. Chemical and functional analysis of hydroxyurea oral solutions. J. Pediatr. Hematol. Oncol.26, 179–184 (2004).
   PubMedGoogle Scholar
• Dresler WFC, Stein R. Ueber den hydroxylharnstoff. Justus Leibigs Ann. Chem. Pharmacol.150, 242–252 (1869).
   Google Scholar
• Saban N, Bujak M. Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer Chemother. Pharmacol.64, 213–221 (2009).
   PubMed Web of Science ®Google Scholar
• Mutschler E, Derendorf H. Drug Actions, Basic Principles and Therapeutic Aspects. Medpharm Scientific Publishers, CRC Press, Stuttgart, Germany (1995).
   Google Scholar
• Charache S, Dover GJ, Moyer MA. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood69, 109–116 (1987).
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD et al. Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N. Engl. J. Med.332, 1317–1322 (1995).
   PubMed Web of Science ®Google Scholar
• Schechter AN, Rodgers GP. Sickle cell anemia: basic research reaches the clinic. N. Engl. J. Med.332, 1372–1374 (1995).
   PubMedGoogle Scholar
• Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a stratergy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl Acad. Sci. USA90, 8925–8928 (1993).
   PubMed Web of Science ®Google Scholar
• Cortellazo S, Finazzi G, Ruggeri M et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med.332, 1132–1136 (1995).
   PubMedGoogle Scholar
• Rosten M. Hydroxyurea: a new antimetabolite in the treatment of psoriasis. Br. J. Dermatol.85, 177–181 (1971).
   PubMed Web of Science ®Google Scholar
• Donovan PB, Kaplan ME, Goldberg JD et al. Treatment of polycythemia vera with hydroxyurea. Am. J. Hematology17, 329–334 (2006).
   Google Scholar
• Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabrasi P. Antineoplastic agents. In: Goodman and Gilman’s the Pharmacological Basis of Therapeutics (10th Edition). McGraw-Hill, NY, USA, 1435–1436 (2001).
   Google Scholar
• Chou JT, Beck WT, Khwaja T, Mayer K, Lein EJ. Synthesis and anticancer activity of novel cyclic N-hydroxyureas. J. Pharm. Sci.66, 1556–1561 (1977).
   PubMedGoogle Scholar
• Kennedy BJ. Hydroxyurea therapy in chronic myelogenous leukemia. Cancer29, 1052–1056 (1972).
   PubMed Web of Science ®Google Scholar
• Piver MS, Howes AE, Suit HD, Marshall N. Effect of hydroxyurea on the radiation response of C3H mouse mammory tumors. Cancer29, 407–412 (1972).
   PubMedGoogle Scholar
• Latagliata R, Spadea A, Cedrone M et al. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome negative myeloproliferative neoplasms. Cancer doi:10.1002/cncr.26194 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood113, 5394–5400 (2009).
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer109, 1114–1124 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia SM, Svarch E, Llanes OA et al. Treatment with moderate doses of hydroxyurea in drepanocytosis. Rev. Cubana Hematol. Immunol. Hemoter.24 (2008).
   Google Scholar
• Ariel IM. Therapeutic effects of hydroxyurea experience with 118 patients with inoperable solid tumors. Cancer25, 705–714 (1970).
   PubMed Web of Science ®Google Scholar
• Borenfreund E, Karim M, Bendlich A. Chromosomal aberrations induced by hyponitrite and hydroxylamine derivatives. J. Nat. Cancer Inst.32, 667–669 (1964).
   PubMed Web of Science ®Google Scholar
• Weinlich G, Fritsch P. Leg ulcers in patients treated with hydroxyurea for myeloproliferative disorders: what is the trigger? Br. J. Dermatol.141, 171–172 (1999).
   PubMed Web of Science ®Google Scholar
• Veale D, Cantwell BMJ, Kerr N, Upfold A, Harris AL. Phase I study of high-dose hydroxyurea in lung cancer. Cancer Chemother. Pharmacol.21, 53–56 (1988).
   PubMed Web of Science ®Google Scholar
• Fishbein WN, Carbone PP. Hydroxyurea – mechanism of action. Science142, 1069–1070 (1963).
   PubMed Web of Science ®Google Scholar
• Frenkel EP, Skinner WN, Smiley JD. Studies on a metabolic defect induced by hydroxyurea (NSC-32065). Cancer Chemother. Rep.40, 19–22 (1964).
   PubMedGoogle Scholar
• Krakoff IH, Brown NC, Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res.28, 1559–1565 (1968).
   PubMed Web of Science ®Google Scholar
• Lassmann G, Thelander L, Graslund A. EPR stopped-flow studies of the reaction of the tyrosyl radical of protein R2 from ribonucleotide reductase with hydroxyurea. Biochem. Biophys. Res. Commun.188, 879–887 (1992).
   PubMedGoogle Scholar
• Sato K, Akaike T, Sawa T et al. Nitric oxide generation from hydroxyurea via copper-catalyzed peroxidation and implications for pharmacological actions of hydroxyurea. Jpn. J. Cancer Res.88, 1199–1204 (1997).
   PubMedGoogle Scholar
• Wawra E, Wintersbeger E. Does hydroxyurea inhibit DNA replication in mouse cells by more than one mechanism? Mol. Cell Biol.3, 297–304 (1983).
   PubMed Web of Science ®Google Scholar
• Young CW, Schochetman G, Karnofski DA. Hydroxyurea-induced inhibition of deoxyribonucleotide synthesis: studies in intact cells. Cancer Res.27, 526–529 (1967).
   PubMed Web of Science ®Google Scholar
• Vogl SE, Camacho F, Kaplan BH, Lerner H, Cinberg J. Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity. Cancer52, 2011–2016 (1983).
   PubMedGoogle Scholar
• Sinclair WK. The combined effect of Hydroxyurea and x-rays on Chinese hamster cells in vitro. Cancer Res.28, 198–206 (1968).
   PubMed Web of Science ®Google Scholar
• Tracewell WG, Trump DL, Vaughan WP, Smith DC, Gwilt PR. Population pharmacokinetics of hydroxyurea in cancer patients. Cancer Chemother. Pharmacol.35, 417–422 (1995).
   PubMed Web of Science ®Google Scholar
• Budavari S. The Merck Index (12th Edition). Merck & Co. Inc., NJ, USA, 833 (1996).
   Google Scholar
• Neil MJO, Heckleman PE, Koch CB, Roman KJ. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (14th Edition). Merck Research Laboratories Division of Merck & Co. Inc., NJ, USA, 4848 (2006).
   Google Scholar
• Martindale W, Reynolds JEF, Prasad AB. Martindale The Extra Pharmacopoeia (28th Edition). Reynolds JEF (Ed.). Published by Direction of the Council of The Pharmaceutical Society of Great Britain, UK, 212 (1982).
   Google Scholar
• Children’s Oncology Group. Pharmacology Manual. Cartwright J, Sinsabaugh D, Henry D (Eds). March revision, 87 (2003).
   Google Scholar
• Miller S, Murphy P. The use of hydroxyurea as adjunct treatment for human immunodeficiency virus. J. Pediatr. Pharm. Pract.4, 107–109 (1999).
   Google Scholar
• WHO International Agency for Research on Cancer. Hydroxyurea, International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risk to Humans. IARC Press, Lyon, France (2000).
   Google Scholar
• Rodriguez GI, Kuhn JG, Weiss GR et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood91, 1533–1541 (1998).
   PubMed Web of Science ®Google Scholar
• Belt RJ, Haas CD, Kennedy J, Taylor S. Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer46, 455–462 (1980).
   PubMedGoogle Scholar
• Newman EM, Carroll M, Akman SA et al. Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. Cancer Chemother. Pharmacol.39, 254–258 (1997).
   PubMedGoogle Scholar
• Hydroxyurea. British Columbia Cancer Agency (BCCA), Cancer Drug Manual, BC, Canada (2006).
   Google Scholar
• Andrae U. Evidence for the involvement of cytochrome P-450-dependent monooxygenase(s) in the formation of genotoxic metabolites from N-hydroxyurea. Biochem. Biophys. Res. Commun.118, 409–415 (1984).
   PubMed Web of Science ®Google Scholar
• DeSesso JM, Scialli AR, Goeringer GC. D-mannitol, a specific hydroxyl free radical scavenger, reduces the developmental toxicity of hydroxyurea in rabbits. Teratology,49, 248–259 (1994).
   PubMedGoogle Scholar
• King SB. N-hydroxyurea and acyl nitroso compounds as nitroxyl (HNO) and nitric oxide (NO) donors. Curr. Top. Med. Chem.5, 665–673 (2005).
   PubMed Web of Science ®Google Scholar
• Kovacic P. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signalling and clinical applications. Med. Hypothesis.76, 24–31 (2011).
   PubMedGoogle Scholar
• Donehower RC. An overview of the clinical experience with hydroxyurea. Semin. Oncol.19(Suppl. 9), 11–19 (1992).
   PubMed Web of Science ®Google Scholar
• Burkitt MJ, Raafat A. Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders. Blood107, 2219–2222 (2006).
   PubMed Web of Science ®Google Scholar
• Beitler JJ, Smith RV, Haynes H et al. A Phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck. Invest. New Drugs16, 161–169 (1998).
   PubMedGoogle Scholar
• Brockstein B, Haraf DJ, Stenson K et al. A Phase I–II study of concomitant chemoradiotherapy with paclitaxel (one hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann. Oncol.11(6), 721–728 (2000).
   PubMedGoogle Scholar
• Beitler JJ, Anderson P, Haynes H et al. Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix. Int. J. Radiat. Oncol. Biol. Phys.52, 637–642 (2002).
   PubMedGoogle Scholar
• Seiwert TY, Haraf DJ, Cohen EEW et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J. Clin. Oncol.26, 1732–1741 (2008).
   PubMed Web of Science ®Google Scholar
• Salama JK, Haraf DJ, Stenson KM et al. A randomized Phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0–1 head and neck cancers. Ann. Oncol.22(10), 2304–2309 (2011).
   PubMedGoogle Scholar
• Haraf DJ, Kies M, Rademaker AW et al. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J. Clin. Oncol.17, 638–644 (1999).
   PubMed Web of Science ®Google Scholar
• Spencer SA, Harris J, Wheeler RH et al. RTOG 96–10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int. J. Radiat. Oncol. Biol. Phys.51, 1299–1304 (2001).
   PubMed Web of Science ®Google Scholar
• Salama JK, Haraf DJ, Stenson K, Milano MT, Witt ME, Vokes EE. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J.11, 140–146 (2005).
   PubMedGoogle Scholar
• Brockstein B, Haraf DJ, Stenson K et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J. Clin. Oncol.16, 735–744 (1998).
   PubMed Web of Science ®Google Scholar
• Kao J, Genden EM, Gupta V et al. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer. Cancer117, 318–326 (2011).
   PubMedGoogle Scholar
• Kies MS, Haraf DJ, Rosen F et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J. Clin. Oncol.19, 1961–1969 (2001).
   PubMedGoogle Scholar
• Rosen FR, Haraf DJ, Kies MS et al. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin. Cancer Res.9, 1689–1697 (2003).
   PubMed Web of Science ®Google Scholar
• Vokes EE, Stupp R, Haraf D et al. Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. Semin. Oncol.22(3 Suppl. 6), 47–52 (1995).
   PubMed Web of Science ®Google Scholar
• Argiris A, Haraf DJ, Kies MS, Vokes EE. Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist8, 350–360 (2003).
   PubMed Web of Science ®Google Scholar
• Rose PG, Ali S, Watkins E et al. Longterm follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a necologic oncology group study. J. Clin. Oncol.25, 2804–2810 (2007).
   PubMed Web of Science ®Google Scholar
• Mabro M, Louvet C, André T et al. Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am. J. Clin. Oncol.26, 254–258 (2003).
   PubMed Web of Science ®Google Scholar
• Jakobsen A, Pfeiffer P, Hansen F, Sandberg E, Aabo K. Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer. Acta Oncol.40, 63–66 (2001).
   PubMedGoogle Scholar
• Di Costanzo F, Gasperoni S, Malacarne P et al. High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for clinical research. Am. J. Clin. Oncol.21, 369–375 (1998).
   PubMed Web of Science ®Google Scholar
• Di Costanzo F, el-Taani H, Parriani D et al. Hydroxyurea may increase the activity of fluorouracil plus folinic acid in advanced gastrointestinal cancer: Phase II study. Cancer Invest.14, 234–238 (1996).
   PubMedGoogle Scholar
• Wadler S, Brain C, Catalano P, Einzig Al, Cella D, Benson AB. Randomized Phase II trial of either fluorouracil, parenteral hydroxyurea, IFN-α-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: Eastern Cooperative Oncology Group study E6296. Cancer J.8, 282–286 (2002).
   PubMedGoogle Scholar
• Yen Y, Chow W, Leong L et al. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California cancer consortium trial.Cancer Chemother. Pharmacol.50, 353–359 (2002).
   PubMed Web of Science ®Google Scholar
• Taïeb J, Artru P, Baujat B et al. Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. Eur. J. Cancer,38, 661–666 (2002).
   PubMedGoogle Scholar
• Stewart DJ, Tomiak EM, Goss G et al. Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer. Lung Cancer15, 115–123 (1996).
   PubMed Web of Science ®Google Scholar
• Blumenreich MS, Kellihan MJ, Joseph UG et al. Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A Phase I trial. Cancer71, 2828–2832 (1993).
   PubMedGoogle Scholar
• Raschko JW, Akman SA, Leong LA et al. Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. Cancer Chemother. Pharmacol.35, 161–164 (1994).
   PubMedGoogle Scholar
• Sharon R, Tatarsky I, Ben-Arieh Y. Treatment of polycythemia vera with hydroxyurea. Cancer57, 718–720 (1986).
   PubMed Web of Science ®Google Scholar
• Kannedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea therapy. Arch. Dermatol.111, 183–187 (1975).
   PubMedGoogle Scholar
• Brincker H, Christensen BE. Acute mucocutaneous toxicity following high dose hydroxyurea. Cancer Chemother. Pharmacol.32, 496–497 (1993).
   PubMedGoogle Scholar
• Jackson GH, Wallis J, Ledingham J, Lennard A, Proctor SJ. Hydroxyurea-induced acute alveolitis in a patient with chronic myeloid leukaemia. Cancer Chemother. Pharmacol.27, 168–169 (1990).
   PubMedGoogle Scholar
• Jabr FI, Ali S, Ali T. Hydroxyurea-induced hemolytic anemia in a patient with essential thrombocythemia. Am. J. Hematol.77, 374–376 (2004).
   PubMedGoogle Scholar
• Tauscher J, Siegel J, Petrides PE. Hydroxyurea induced oscillations in twelve patients with polycythemia vera. Haematologica95, 1227–1229 (2010).
   PubMed Web of Science ®Google Scholar